AJANTPHARM - Ajanta Pharma Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

AJANTPHARM

53/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹2897.30+91.30(+3.25%)

Market Open as of Apr 13, 2026, 15:30 IST

Select time range

Pros

Smart Money: Smart money has been increasing their position in the stock.

Balance Sheet: Strong Balance Sheet.

Past Returns: Outperforming stock! In past three years, the stock has provided 32.1% return compared to 10.7% by NIFTY 50.

Growth: Good revenue growth. With 37.8% growth over past three years, the company is going strong.

Profitability: Very strong Profitability. One year profit margin are 19%.

Size: Market Cap wise it is among the top 20% companies of india.

Technicals: Bullish SharesGuru indicator.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Valuation
Market Cap	36.13 kCr
Price/Earnings (Trailing)	35.62
Price/Sales (Trailing)	6.78
EV/EBITDA	24.37
Price/Free Cashflow	36.58
MarketCap/EBT	27.79
Enterprise Value	36.24 kCr

Fundamentals
Revenue (TTM)	5.33 kCr
Rev. Growth (Yr)	19%
Earnings (TTM)	1.01 kCr
Earnings Growth (Yr)	17.6%

Profitability
Operating Margin	24%
EBT Margin	24%
Return on Equity	23.51%
Return on Assets	17.89%
Free Cashflow Yield	2.73%

Growth & Returns
Price Change 1W	5.5%
Price Change 1M	-4.6%
Price Change 6M	20%
Price Change 1Y	12.7%
3Y Cumulative Return	32.1%
5Y Cumulative Return	20.2%
7Y Cumulative Return	22.8%
10Y Cumulative Return	11.3%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-376.52 Cr
Cash Flow from Operations (TTM)	1.16 kCr
Cash Flow from Financing (TTM)	-733.41 Cr
Cash & Equivalents	89.81 Cr
Free Cash Flow (TTM)	839.31 Cr
Free Cash Flow/Share (TTM)	67.19

Balance Sheet
Total Assets	5.67 kCr
Total Liabilities	1.36 kCr
Shareholder Equity	4.32 kCr
Current Assets	3.39 kCr
Current Liabilities	1.16 kCr
Net PPE	1.74 kCr
Inventory	812.14 Cr
Goodwill	0.00

Capital Structure & Leverage
Debt Ratio	0.04
Debt/Equity	0.05
Interest Coverage	64.59
Interest/Cashflow Ops	46.81

Dividend & Shareholder Returns
Dividend/Share (TTM)	28
Dividend Yield	1%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	-2.5%

Technical Indicators
RSI (14d)	33.95
RSI (5d)	54.13
RSI (21d)	41.83
MACD Signal	Sell
Stochastic Oscillator Signal	Buy
SharesGuru Signal	Buy
RSI Signal	Hold
RSI5 Signal	Hold
RSI21 Signal	Hold
SMA 5 Signal	Buy
SMA 10 Signal	Buy
SMA 20 Signal	Sell
SMA 50 Signal	Sell
SMA 100 Signal	Sell

Shareholder Name	Holding %
Yogesh M Agrawal, trustee Yogesh Agrawal Trust	14.47%
Rajesh M Agrawal, trustee Rajesh Agrawal Trust	14.47%
Ravi P Agrawal, trustee Ravi Agrawal Trust	13%
Aayush M Agrawal, trustee Aayush Agrawal Trust	11.3%
Gabs Investments Pvt Ltd	10.08%
Uti-Flexi Cap Fund	3.19%
Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal	2.68%
Tata Aia Life Insurance Co Ltd-Whole Life Mid Cap Equity Fund-Ulif 009 04/01/07 Wle 110	1.77%
Kotak Small Cap Fund	1.59%
Canara Robeco Mutual Fund A/C Canara Robeco Small Cap Fund	1.48%
Aditya Birla Sun Life Trustee Private Limited A/C Aditya Birla Sun Life Midcap Fund	1.1%
Ravi P Agrawal	0.23%
Aayush M Agrawal	0.02%
Mannalal B. Agrawal	0%

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	3.97 LCr	58.94 kCr	-8.20%	-2.00%	36.34	6.73	-	-
LUPIN	Lupin	1.06 LCr	26.49 kCr	0.00%	+17.60%	22.76	3.99	-	-
DRREDDY	Dr. Reddy's Lab	1.03 LCr	36.09 kCr	-4.50%	+11.20%	18.45	2.85	-	-
CIPLA	Cipla	97.89 kCr	29.37 kCr	-7.80%	-17.20%	21.52	3.33	-	-
AUROPHARMA	Aurobindo Pharma	77.83 kCr	33.73 kCr	+3.40%	+23.80%	22.32	2.31	-	-

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	10.4%	4,648	4,209	3,743	3,341	2,890	2,588
Other Income	10.7%	94	85	99	116	26	92
Total Income	10.5%	4,743	4,293	3,841	3,457	2,916	2,680
Cost of Materials	-9.8%	847	939	878	779	706	560
Purchases of stock-in-trade	50.9%	250	166	146	136	90	112
Employee Expense	21.1%	1,090	900	785	646	548	486
Finance costs	222.1%	21	7.21	5.84	10	8.27	12
Depreciation and Amortization	6.7%	144	135	131	125	116	96
Other expenses	14.8%	1,228	1,070	1,124	934	698	763
Total Expenses	11.8%	3,553	3,179	3,096	2,547	2,015	2,012
Profit Before exceptional items and Tax	6.7%	1,189	1,114	745	909	900	668
Exceptional items before tax	-	0	0	0	0	0	-3.92
Total profit before tax	6.7%	1,189	1,114	745	909	900	664
Current tax	-3.1%	312	322	197	192	261	186
Deferred tax	-76%	-43.53	-24.3	-39.97	5.13	-15.05	9.92
Total tax	-9.8%	269	298	157	197	246	196
Total profit (loss) for period	12.8%	920	816	588	713	654	468
Other comp. income net of taxes	547.4%	1.85	0.81	15	-7.97	-6.45	5.56
Total Comprehensive Income	12.9%	922	817	603	705	647	473
Earnings Per Share, Basic	13.7%	73.56	64.82	45.89	54.966667	50.06	35.733333
Earnings Per Share, Diluted	13.7%	73.53	64.77	45.89	54.966667	50.06	35.733333

Description	(%) Q/Q	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024
Revenue From Operations	1.6%	1,375	1,354	1,303	1,170	1,146	1,187
Other Income	-58.6%	25	59	26	18	30	19
Total Income	-0.9%	1,400	1,413	1,329	1,189	1,177	1,206
Cost of Materials	7.8%	235	218	207	191	210	207
Purchases of stock-in-trade	1.9%	54	53	52	80	79	46
Employee Expense	4.4%	331	317	303	280	265	261
Finance costs	71.5%	5.1	3.39	5.26	6.07	7.91	6.02
Depreciation and Amortization	2.4%	44	43	41	40	36	34
Other expenses	-4.1%	376	392	373	310	302	353
Total Expenses	-2.9%	1,041	1,072	998	919	869	916
Profit Before exceptional items and Tax	5.3%	359	341	331	269	307	290
Total profit before tax	5.3%	359	341	331	269	307	290
Current tax	11.7%	87	78	74	62	95	76
Deferred tax	-331.1%	-2.05	2.32	2.29	-17.81	-20.34	-2.35
Total tax	5%	85	81	76	44	75	74
Total profit (loss) for period	5.4%	274	260	255	225	233	216
Other comp. income net of taxes	-79.3%	2.51	8.3	0.16	2.04	1.44	5.71
Total Comprehensive Income	3%	276	268	256	227	234	222
Earnings Per Share, Basic	5.4%	21.91	20.83	20.44	18	18.6	17.27
Earnings Per Share, Diluted	5.5%	21.91	20.82	20.43	18	18.59	17.26

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	8.8%	4,322	3,971	3,411	3,141	2,719	2,196
Other Income	3.5%	120	116	133	140	104	184
Total Income	8.7%	4,442	4,088	3,544	3,280	2,822	2,381
Cost of Materials	-9.8%	847	939	878	773	704	556
Purchases of stock-in-trade	13.7%	184	162	149	116	101	99
Employee Expense	21.2%	1,011	834	720	586	498	438
Finance costs	-37.9%	4.6	6.8	5.23	9.12	6.9	9.1
Depreciation and Amortization	6.1%	140	132	127	121	111	91
Other expenses	16.6%	1,094	938	986	831	573	562
Total Expenses	9.1%	3,262	2,991	2,844	2,380	1,920	1,764
Profit Before exceptional items and Tax	7.6%	1,180	1,097	700	901	902	617
Exceptional items before tax	-	0	0	0	0	0	-3.92
Total profit before tax	7.6%	1,180	1,097	700	901	902	613
Current tax	-7.2%	258	278	144	171	217	168
Deferred tax	-62.4%	5.14	12	-2.93	9.51	9.77	3.45
Total tax	-9.3%	263	290	141	181	226	172
Total profit (loss) for period	13.6%	917	807	559	720	676	441
Other comp. income net of taxes	-94%	-5.83	-2.52	-2.27	0.36	-1.33	-2.55
Total Comprehensive Income	13.2%	911	805	556	720	674	439
Earnings Per Share, Basic	14.5%	73.28	64.11	43.61	55.52	51.726667	33.7
Earnings Per Share, Diluted	14.6%	73.25	64.06	43.61	55.52	51.726667	33.7

Description	(%) Q/Q	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024
Revenue From Operations	-1.1%	1,207	1,220	1,209	1,014	1,102	1,129
Other Income	-66.2%	26	75	41	18	33	40
Total Income	-4.9%	1,232	1,295	1,249	1,032	1,135	1,169
Cost of Materials	7.8%	235	218	207	191	210	207
Purchases of stock-in-trade	11.8%	58	52	50	57	40	43
Employee Expense	4.5%	306	293	281	258	246	242
Finance costs	422.2%	1.87	0.73	0.73	0.67	2.48	0.73
Depreciation and Amortization	0%	42	42	40	39	35	33
Other expenses	-11.1%	305	343	335	274	266	317
Total Expenses	-6.5%	910	973	920	804	803	860
Profit Before exceptional items and Tax	0%	322	322	329	228	332	309
Total profit before tax	0%	322	322	329	228	332	309
Current tax	10.8%	73	66	71	39	76	71
Deferred tax	-29.8%	4.84	6.47	3.29	-4.38	3.32	3.09
Total tax	7%	77	72	74	35	80	74
Total profit (loss) for period	-2%	245	250	255	193	252	235
Other comp. income net of taxes	-52.8%	0.19	0.47	-3.25	-1.43	-0.41	-1.56
Total Comprehensive Income	-2%	245	250	252	192	252	233
Earnings Per Share, Basic	-1.9%	19.61	19.98	20.41	15.46	20.16	18.75
Earnings Per Share, Diluted	-1.9%	19.61	19.97	20.4	15.45	20.15	18.74

Category	AJANTPHARM	Pharmaceuticals
PE	34.57	33.77
PS	6.58	4.66
Growth	14.8 %	8 %

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-48.9%	90	175	64	129	262	330
Current investments	93.6%	849	439	677	330	213	510
Loans, current	-29.9%	2.08	2.54	20	34	23	17
Total current financial assets	32.9%	2,395	1,803	1,794	1,761	1,646	1,918
Inventories	-10.2%	812	904	846	828	786	816
Total current assets	19.9%	3,394	2,830	2,786	2,722	2,563	2,825
Property, plant and equipment	7.1%	1,740	1,625	1,360	1,384	1,397	1,408
Capital work-in-progress	-17.1%	146	176	349	256	205	209
Investment property	-	0	0	0	0	0	0
Non-current investments	0%	25	25	25	19	25	25
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	-3%	33	34	34	28	36	36
Total non-current assets	4.9%	2,279	2,172	1,996	1,907	1,870	1,845
Total assets	13.1%	5,672	5,015	4,790	4,638	4,433	4,679
Borrowings, non-current	-	0	0	2.42	0	0	1.25
Total non-current financial liabilities	5.7%	38	36	374	25	24	27
Provisions, non-current	-51.9%	39	80	88	40	23	24
Total non-current liabilities	-13.6%	198	229	577	175	152	152
Borrowings, current	12541.5%	202	2.59	0	1.49	0.91	0.18
Total current financial liabilities	26.3%	1,062	841	421	773	681	1,069
Provisions, current	0%	23	23	0	18	12	14
Current tax liabilities	5%	43	41	55	45	82	33
Total current liabilities	16.5%	1,160	996	537	895	799	1,139
Total liabilities	10.8%	1,357	1,225	1,114	1,071	951	1,291
Equity share capital	0%	25	25	25	25	25	25
Total equity	13.9%	4,315	3,790	3,677	3,567	3,482	3,388
Total equity and liabilities	13.1%	5,672	5,015	4,790	4,638	4,433	4,679

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	37.5%	67	49	27	62	200	269
Current investments	93.6%	849	439	677	330	213	510
Loans, current	-29.9%	2.08	2.54	20	15	22	17
Total current financial assets	22%	2,097	1,719	1,725	1,635	1,559	1,777
Inventories	-9.5%	669	739	694	678	626	684
Current tax assets	-	0	0	0	0	0	0.83
Total current assets	14.5%	2,939	2,567	2,550	2,433	2,306	2,544
Property, plant and equipment	7.1%	1,737	1,622	1,353	1,377	1,389	1,400
Capital work-in-progress	-17.1%	146	176	349	256	205	209
Investment property	-	0	0	0	0	0	0
Non-current investments	0%	43	43	44	37	43	43
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	-4%	49	51	52	46	54	54
Total non-current assets	4.4%	2,064	1,978	1,853	1,776	1,743	1,753
Total assets	9.9%	5,003	4,554	4,412	4,217	4,049	4,305
Total non-current financial liabilities	12.5%	28	25	22	24	24	26
Provisions, non-current	-51.9%	39	80	67	40	23	24
Total non-current liabilities	-13.8%	188	218	204	174	152	150
Total current financial liabilities	4.9%	558	532	502	514	447	859
Provisions, current	0%	23	23	21	18	12	14
Current tax liabilities	131.2%	38	17	58	37	57	11
Total current liabilities	-3.4%	687	711	678	629	541	908
Total liabilities	-5.8%	875	929	882	804	693	1,058
Equity share capital	0%	25	25	25	25	25	25
Total equity	13.9%	4,128	3,625	3,530	3,414	3,356	3,246
Total equity and liabilities	9.9%	5,003	4,554	4,412	4,217	4,049	4,305

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	222.1%	21	7.21	5.84	10	-	-
Change in inventories	-467.7%	-74.51	-12.3	-22.37	-25.66	-	-
Depreciation	6.7%	144	135	131	125	-	-
Impairment loss / reversal	91.8%	0.63	-3.49	5.37	7.85	-	-
Unrealised forex losses/gains	-8.5%	-10.31	-9.42	-14.08	-21.19	-	-
Adjustments for interest income	56.8%	59	38	18	4.08	-	-
Share-based payments	-35.9%	3.88	5.49	0.22	0.3	-	-
Net Cashflows from Operations	34.9%	1,480	1,097	943	801	-	-
Income taxes paid (refund)	3.5%	323	312	151	239	-	-
Other inflows (outflows) of cash	-	0	0	0	0.01	-	-
Net Cashflows From Operating Activities	47.4%	1,157	785	792	562	-	-
Cash payment for investment in partnership firm or association of persons or LLP	-	6.25	0	0	25	-	-
Proceeds from sales of PPE	-98.8%	1.14	13	0.73	18	-	-
Purchase of property, plant and equipment	109.9%	318	152	174	149	-	-
Interest received	65.4%	44	27	0.52	0.9	-	-
Other inflows (outflows) of cash	30.6%	0.16	-0.21	4.35	27	-	-
Net Cashflows From Investing Activities	-689.9%	-376.52	65	-559.6	-74.1	-	-
Proceeds from issuing other equity instruments	-	0.01	0	0	0	-	-
Payments to acquire or redeem entity's shares	-9.3%	353	389	1.44	354	-	-
Proceeds from borrowings	110.6%	1.1	0.06	0	0.23	-	-
Repayments of borrowings	-	0	0	0.49	0	-	-
Payments of lease liabilities	-6.7%	15	16	14	17	-	-
Dividends paid	-45.7%	349	642	90	82	-	-
Interest paid	532.4%	17	3.53	2.33	7.35	-	-
Other inflows (outflows) of cash	-	0	0	0.33	0	-	-
Net Cashflows from Financing Activities	30.2%	-733.41	-1,051.06	-107.87	-460.04	-	-
Effect of exchange rate on cash eq.	-260.8%	-1.67	0.26	-0.84	0.95	-	-
Net change in cash and cash eq.	122.4%	46	-200.34	123	29	-	-

AJANTPHARM - Ajanta Pharma Ltd. Share Price

AJANTPHARM

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

AJANTPHARM

AJANTPHARM - Ajanta Pharma Ltd. Share Price

AJANTPHARM

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

AJANTPHARM

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Ajanta Pharma Ltd. do?

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Ajanta Pharma Ltd. do?

Important Disclosure & Data Context